This invention involved a new methodology using novel targets, TMS stimulation and a hypnosis protocol to modulate traits and help chronic pain, addiction, and mental disorders.
Researchers in the laboratories of Prof. Stanley Cohen and Prof Tzu-Hao Cheng have discovered that Supt4h is a potential therapeutic target for reducing toxicity and restoring the functionality of deleterious proteins in Huntington's (HD) and other polyQ diseases.
Dr. Stanley Cohen and colleagues have identified small molecular compounds that may be useful in the treatment of nucleotide repeat diseases. A well-known nucleotide repeat disorder is Huntington's disease.
This invention is a practical extension of Stanford docket S05-170 (photosensitive proteins Channelrhodopsins) and describes an implantable, light-generating device for the optical stimulation of neural
The inventors have identified and developed an archaeal light-driven chloride pump (NpHR) from Natronomonas pharaonis for temporally precise optical inhibition of neural activity. NpHR allows either knockout of single action potentials, or sustained blockade of spiking.
Ion channel dysfunctions lead to a wide array of illnesses including epilepsy, cardiac arrhythmia and type II diabetes. However, the number of clinically approved drugs for restoring normal ion channel function is limited.
Researchers in Dr. Karl Deisseroth's laboratory have developed a novel method to rapidly identify neurophysiological measures associated with psychiatric disease and then use those correlates to screen for therapeutics.
Researchers from Prof. Karl Deisseroth's laboratory have developed techniques for specifically modulating the activity of excitable cells in vivo. This approach introduces light-responsive proteins to create photo-sensitive cells.
Researchers in Prof. Karl Deisseroth's laboratory have developed a novel system for modulating brain activity with moderate intensity focused ultrasound. In this technique, ultrasound is used to increase the intrinsic firing rate of targeted neurons.
Researchers from Prof. Karl Deisseroth's laboratory have developed techniques for specifically modulating the activity of excitable cells in vivo. This approach introduces light-responsive proteins to create photo-sensitive cells.
The inventors have developed a light-driven chloride pump (NpHR or Halo) for temporally precise optical inhibition of neural activity with ordinary yellow light.